Guidelines for Normal Nuchal Translucency Measurement and Follow‑Up

Definition and Clinical Threshold

The American College of Radiology defines a normal nuchal translucency (NT) as < 3.0 mm or below the 99th percentile for crown‑rump length at 11–14 weeks’ gestation; such findings require only the routine second‑trimester anatomic ultrasound without additional specialized follow‑up. 1
An NT measurement ≥ 3.0 mm is considered abnormally elevated and mandates immediate further evaluation regardless of gestational age or concurrent serum marker results. 3
The fixed 3.0 mm cutoff is endorsed as a practical clinical threshold that captures high‑risk pregnancies while maintaining acceptable false‑positive rates. 2

In pregnancies with a normal NT (< 3.0 mm), the American College of Radiology recommends that first‑trimester combined screening incorporate maternal serum markers (PAPP‑A and free β‑hCG) to calculate a comprehensive aneuploidy risk, because NT alone identifies only ~70 % of trisomy 21 cases. 1
Normal NT does not eliminate the need for aneuploidy risk assessment; biochemical markers must be integrated with maternal factors (age, weight, race, prior aneuploidy history) to generate accurate risk estimates. 4

The American College of Radiology advises that a standard second‑trimester anatomic survey at 18–22 weeks remains mandatory even when NT is normal, since only ~50 % of major fetal anomalies are detectable before 14 weeks compared with ~75 % in the second trimester. 2

When NT is normal and no other maternal or fetal risk factors are present, no additional Doppler studies, fetal echocardiography, or specialized imaging are indicated. 4
NT should not be used as an isolated screening test for structural malformations or congenital heart disease, given its low sensitivity (< 25 % detection for major cardiac defects in euploid fetuses). 2

The American College of Radiology stresses that laboratories must monitor sonographer performance, ensuring median NT measurements fall within 0.9–1.1 multiples of the median (MoM) for each operator. 5
Recognizing significant inter‑ and intra‑observer variability, the society recommends standardized measurement technique and ongoing quality assessment through programs such as the Fetal Medicine Foundation or Nuchal Translucency Quality Review. 1

Transvaginal ultrasound may be required in approximately 5 % of patients when transabdominal visualization is suboptimal (e.g., high maternal BMI, multiple prior surgeries, transverse fetal lie), using the same measurement principles as the transabdominal approach. 2